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JPET #241794 -6 -acid protein containing three main domains; a broad complex, tramtrack, bric-a-brac (BTB) domain which facilitates homodimerization of Keap1 and the Keap1-Cul3 interaction, a cysteinerich intervening region (IVR) domain, and a Kelch domain through which Keap1 binds Nrf2 (Baird and Dinkova-Kostova, 2011) . The BTB and IVR domains of Keap1 have been shown to contain key reactive cysteine residues (Cys151, Cys273 and Cys288) that interact with electrophiles, resulting in activation of Nrf2 (Cleasby et al., 2014) and thus transcription of a host of antioxidant response genes.
Targeting the Nrf2 pathway through disruption of the Nrf2-Keap1 complex, specifically via the modification of cysteine residues in the Keap1 BTB and IVR domains, has recently been the focus of drug development strategies for several diseases including, but not limited to, cancer (Ross and Critchlow, 2014) , chronic kidney disease (Rojas-Rivera et al., 2012) , and multiple sclerosis (Phillips and Fox, 2013) . The Nrf2 pathway also holds promise for COPD treatment, where oxidative stress plays a role in pathology and Nrf2 signaling has been found to be dysfunctional (Goven et al., 2008; Yamada et al., 2016) . There are currently several clinical assets, such as Tecfidera ® (dimethyl fumarate, DMF, BG-12), and bardoxolone methyl (CDDOMe) , that target the Nrf2 pathway. Tecfidera ® is approved for use in patients with multiple sclerosis, although interestingly, research now suggests that this drug may be acting through mechanisms in addition to Nrf2, such as the hydroxycarboxylic acid receptor 2 (Chen et al., 2014) . Currently, bardoxolone methyl is in a phase 3 trial (CATALYST) in patients with connective tissue disease-associated pulmonary arterial hypertension and a phase 2/3 trial is planned in patients with chronic kidney disease caused by Alport syndrome. In the phase 3 BEACON trial for chronic kidney disease in type 2 diabetics, bardoxolone methyl was terminated due to adverse cardiovascular side effects (de Zeeuw et al., 2013) which could be due to off-target effects on endothelin signaling (Chin et al., 2014) . These findings highlight the need to develop more potent and selective Nrf2 activators for use in diseases in which Nrf2
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-9 -Corning, NY) submerged for the first 3 days, during which time the culture medium was changed on day 1 and every other day thereafter. ALI was created once the cells reached 100% confluence, by removing the apical medium and restricting the culture feeding to the basolateral compartment of the plates. The culture medium was changed every other day until the cells were differentiated at approximately 28 days. The human biological samples were sourced ethically and their research use was in accord with the terms of the informed consents.
Studies were performed in accordance with the Declaration of Helsinki.
Transfections. NHBE cells were plated at 5 x 10 4 cells per well in 24-well plates and were transfected the following day with 25 nM non-targeting or Nrf2 siRNA (Dharmacon/Thermo Scientific, Waltham, MA) for 48 hours according to the supplier's general transfection protocol.
The wells were aspirated and the cells were treated with vehicle (dimethyl sulfoxide (DMSO), Sigma-Aldrich) or compound in complete BEBM media without antibiotics for 24 hours at 37°C
and 5% CO2. The wells were aspirated and the cells were lysed with Complete Lysis-M Buffer (Roche, Indianapolis, IN) on ice for protein analysis or lysis buffer from the Illustra RNA Kit (GE Healthcare Life Sciences, Pittsburgh, PA) for mRNA determination.
Western Blotting. Whole-cell lysate protein concentrations were determined with a colorimetric assay detection kit (BioRad, Hercules, CA) and were subjected to immunoblot analysis. Equal amounts of denatured protein lysates were separated on a 12.5% Tris-HCl
Criterion™ precast gel and were transferred to a nitrocellulose membrane (BioRad). The membrane was blocked with 5% (w/v) ECL Prime blocking agent (GE Healthcare Life Sciences, Piscataway, NJ) in PBS without Ca +2 and Mg +2 containing 0.1% (v/v) Tween 20 (Sigma-Aldrich).
The blot was exposed to rabbit polyclonal anti-human heme oxygenase-1 (HO-1) (diluted 1:2000, Enzo Life Sciences, Farmingdale, NY,) overnight at 4°C. Two phosphate-buffered saline (PBS)/0.1% Tween wash steps were performed followed by the addition of an anti-rabbit IgG horseradish peroxidase-conjugated secondary antibody (diluted 1:5000, Cell Signaling
This article has not been copyedited and formatted. The final version may differ from this version. Analysis of Gene Expression. For human samples, RNA was isolated using the Illustra RNA Kit (GE Healthcare Life Sciences) and TaqMan was performed using probe/primer pairs to detect human NAD(P)H:quinone oxireductase 1 (NQO1), HO-1, glutamate-cysteine ligase modifier subunit (GCLM) and thioredoxin reductase 1 (TXNRD1) (Applied Biosystems, Foster City, CA). Data was normalized to 18S levels using the Ct method. For rodent samples, RNA was isolated using Trizol Reagent (Life Technologies). 500 ng of RNA from each sample was reverse transcribed in a 20 µl reaction using QuantiTect Reverse Transcription (Qiagen, Germantown, MD) according to recommended conditions. Real-time PCR was performed on the ABI ViiA7 Real-time PCR system (Applied Biosystems) using 18S as the internal control. The cDNA was amplified with probe/primer pairs for mouse or rat Nqo1, sulfiredoxin 1 (Srxn1) and Txnrd1 (obtained from TaqMan Gene Expression Assays, Applied Biosystems) using universal master mix (Applied Biosystems). An identical threshold cycle (Ct) was applied for each gene of interest. The comparative Ct (∆∆Ct) relative quantification method was used to calculate the relative mRNA levels of target genes as described in the Applied Biosystems Chemistry Guide.
For NanoString gene expression profiling, a set of Nrf2-dependent genes selected from the literature was used to generate a code set (NanoString Technologies, Seattle, WA) including JPET #241794
-11 -Mini RNA Isolation Kit, GE Healthcare Life Sciences) was used for RNA quantification according to the manufacturer's instructions. Data was analyzed using nSolver Analysis Software, version 1.1.
Nrf2
Nuclear Translocation. NHBE cells were cultured on plastic as described above until >80% confluent. On the day of the assay, vehicle (DMSO), PSTC or tert-butyl hydroquinone (tBHQ) (Crescent Chemical Co., Islandia, NY) was added for 6 hours and then nuclear extracts were generated using the protocol included with the TransAm Nrf2 kit (Active Motif, Carlsbad CA). Protein concentrations were determined with a colorimetric assay detection kit (BioRad). Nuclear samples were then assayed using the TransAm Nrf2 kit. For siRNA studies, cells were transfected as described above for 48 hours followed by 6 hours of treatment with vehicle or compounds. Cells were then processed as described above.
NQO1 Enzyme Activity Assay. NQO1 specific enzyme activity was measured using an assay adapted from Prochaska et al. (Prochaska and Santamaria, 1988 Crude cell lysates were generated and assayed for glutathione content according to the manufacturer's protocol using 5% sulfosalicylic acid (Arbor Assays DetectX ® Glutathione Fluorescent Detection Kit, Ann Arbor, MI). For rat samples, glutathione content was determined following the instructions of the manufacturer (Cayman Chemicals, Ann Arbor, MI). One hundred mg of lung tissue was normalized to 0.10 mg/ml with 1X MES buffer and homogenized using a gentleMACS Dissociator (Miltenyi Biotec Inc., Auburn, CA). Sample were centrifuged at 228 g for 10 minutes at 4°C and then clarified at 13,000 g for 5 min at 4°C. Sample were deproteinated at a 1:1 ratio with metaphosporic acid (500 l of samples + 500 l of MPA) and vortexed immediately. Fifty l of 4 M TEAM reagent (Sigma-Aldrich) was then added to increase the pH, and samples were diluted at 1:5 and/or 1:10 for glutathione assay. -15 -of ice cold PBS were injected and removed sequentially through the tubing. Following centrifugation at 140g for 2 minutes, cell pellets from the 4 aliquots were combined. For rats, the trachea was cannulated with a gavage needle attached to a 5 ml syringe. One 3 ml aliquot of ice cold PBS was injected and removed through the gavage needle, and the resulting BAL fluid was centrifuged at 140g for 2 minutes. Total cells were counted using a hemocytometer.
Differential cell analysis was performed on cytospins using Wright-Giemsa stain.
Cytokine Analysis. Lung tissue was weighed, suspended in 1 ml PBS/gram of tissue, and homogenized using a gentleMACS Octo Dissociator with M tubes (Miltenyi Biotec Inc., Auburn, CA). The tissue homogenate was then centrifuged at 2500 g for 10 minutes, and the resulting supernatant centrifuged at 400 g for 10 minutes. Keratinocyte-derived cytokine (KC, CXCL1) levels were measured using a mouse ELISA kit purchased from R&D Systems (Minneapolis, MN). Assays were performed according to the manufacturer's instructions.
Ozone Exposure. Han Wistar rats were exposed to ozone generated by an Oxycycler ozonator (Biospherix Inc., Lacona, NY) in which compressed air and oxygen were passed through the ozonator and flowed into a plexiglass chamber containing the animals. Twenty-four hours prior to ozone injury, rats received a single oral administration of vehicle (0.9% DMSO, 7% DMA,10% Cremophor El, 82.1% water) or compound. Rats were exposed to 1 ppm of ozone for a 3 hour period. Ozone concentrations, humidity and CO2 within the chamber were constantly monitored by the Oxycycler watview software and using an independent ozone monitor (Teledyne Advanced Pollution Instrumentation Inc, Thousand Oaks, CA). The rats were euthanized 15 minutes after injury by intraperitoneal administration of 1 ml of Fatal Plus analysis. For analysis of drug concentration, the blood samples were thawed, vortexed, and centrifuged (1207 g, 4°C, 10 minutes). A 50 µL aliquot of the supernatant was vortexed with 50 µL of water for injection onto the mass spectrometer. Analysis of the samples was performed using liquid chromatography/tandem mass spectrometric detection. Twenty L injections were made onto the liquid chromatography/tandem mass spectrometric system using Agilent 1100
Series binary pumps (Agilent Technologies, Santa Clara, CA) and a CTC PAL Autosampler (CTC Analytics, Zwingen, Switzerland). The mobile phase consisted of a gradient that transitioned linearly from 95% aqueous 10 mM ammonium formate, pH3 / 5% acetonitrile to 66% acetonitrile over two minutes (500 L/min flow rate), then to 95% acetonitrile over an additional minute, was held at those conditions for 0.5 minutes, and reconditioned back to initial conditions for an additional 2.5 minutes. An Agilent SB-C18 4.6x50mm analytical column was used to retain the analytes. The eluent flowed into a Sciex API 4000 triple quadrupole mass spectrometer (Applied Biosystems, Foster City, California) using negative-ion TIS multiple-reaction monitoring for the first 3. . 1A ), is a potent disrupter (pIC50 = 7.1) of the interaction between Cul3 and Keap1 as measured by a Cul3-Keap1 FRET assay (Cleasby et al., 2014) designed to identify inhibitors of this protein-protein interaction. Further evaluation of PSTC in BEAS-2B cells (Davies et al., 2016) showed that it was a potent (pEC50 = 7.7) inducer of NQO1 specific enzyme activity. PSTC was prepared by heating 2-hydroxy-6-(trifluoromethyl)benzaldehyde with 2-(pyridin-3-ylsulfonyl)acetic acid in acetic anhydride. Although PSTC was stable under acidic conditions, under basic conditions it was converted to a salt of the hydroxy-acid (Fig. 1B) with a mixture containing each compound observed at physiological pH. The in vitro profiling of either PSTC or the corresponding hydroxy-acid gave similar results in the Cul3-Keap1 FRET assay (pIC50 = 7.1/6.9) and the BEAS-2B cell assay (pEC50 = 7.7/7.0) supporting the assertion that the two compounds exist as an equilibrium mixture at physiological pH. When tested in a selectivity panel containing 50 enzymes, receptors, ion channels and phenotypic cell health screens, the two compounds exhibited activity against cannabinoid receptor type 2 (pXC50 = 5 for each compound).
Comparator Nrf2 activators, CDDO-Me, SFN and DMF, exhibited pEC50 values of 8.4, 5.8 and 5.6, respectively, in the induction of NQO1 specific enzyme activity in BEAS-2B cells. In our experiments, compounds were used at concentrations at the upper plateau of their respective concentration response curves in order to achieve maximum pharmacologic effect.
In the selectivity panel, CDDO-Me exhibited activity (pXC50 > 5) against serotonin 2A receptor (6.6), serotonin 2C receptor (5.9), adrenergic 1b receptor (6.1), adrenergic 2c receptor (5.4), dopamine 1 receptor (5.7), dopamine 2 receptor (5.8), histamine 1 receptor (6.6), vasopressin 1a receptor (6.7), phosphodiesterase 4B (5.6), L-type calcium channel (CaV1.2) (5.3), aurora B JPET #241794
-18 -(STK12) (5.4), muscarinic 1 receptor (5.6), muscarinic 2 receptor (5.7), neurokinin 1 receptor (6.5), opioid receptor (5.8),opioid receptor (5.7), cell health -mitochondrial integrity (5.9), cell health -membrane permeability (5.9), and cell health -nucleus size (6.1); SFN exhibited activity against potassium voltage-gated channel subfamily KQT member 1/ potassium voltagegated channel subfamily E regulatory subunit 1 (6.1); and DMF exhibited no activity (pXC50 < 5).
PSTC Induces Nrf2 Nuclear Translocation in Normal Human Bronchial Epithelial
Cells via an Nrf2-Dependent Mechanism. To evaluate the ability of PSTC to repress Keap1
and thus activate Nrf2, we monitored Nrf2 nuclear translocation in NHBE cells. Cells were transfected with a non-targeting or Nrf2 siRNA for 48 hours, and then exposed to PSTC (1 M)
or a comparator Nrf2 activator, tBHQ (50 M), for 6 hours. PSTC induced an increase in Nrf2 nuclear translocation and this increase was abolished by pre-treatment with Nrf2 siRNA but not non-targeting siRNA (Fig. 2) . Similar results were seen in tBHQ-treated cells. In separate studies, treatment of NHBE cells with PSTC (10 M) for 6 or 24 hours did not induce significant changes in NRF2 gene expression (data not shown), suggesting that the Nrf2 nuclear translocation induced by PSTC is not a result of increased Nrf2 synthesis. Collectively, these data show that PSTC disrupts the Nrf2-Keap1 complex, thereby inducing nuclear translocation of Nrf2, and confirm the specificity of the assay for Nrf2.
Nrf2-Regulated Phase II Enzymes are Induced by PSTC via an Nrf2-Dependent
Mechanism. We next analyzed whether PSTC-induced inhibition of Keap1, and subsequent nuclear translocation of Nrf2, would lead to downstream induction of Nrf2-dependent genes and proteins. Treatment of cells with 10 M PSTC for 6 hours increased expression of multiple Nrf2-dependent genes, including components of the glutathione synthesis/utilization pathway (GCLM, GCLC, GSR), quinone detoxification (NQO1), NADPH production (G6PD, PGD) and iron sequestration pathways (HO-1, FTH1) (Fig. 3A) . Up-regulation of these genes was Exposure of vehicle (DMSO)-treated NHBE cells to the anti-oxidant, NAC, or the oxidant, tBHP, alone caused up-regulation and depletion, respectively, of total glutathione levels, while pretreatment with PSTC prior to tBHP exposure protected cells from glutathione depletion in a concentration-dependent manner (Fig. 4) . Similarly CDDO-Me, SFN, and DMF protected NHBE cells against glutathione depletion in this model.
PSTC does not Inhibit the Activation of NF-B in BEAS-2B Cells or mTOR-
Dependent S6 Phosphorylation in HEK293 Cells. Previous reports have established diverse effects of CDDO-Me, including its inhibition of the NF-B signaling pathway via direct interaction with IKK2 (Ahmad et al., 2006) , as well as inhibition of mTOR (Deeb et al., 2007) . In order to address the specificity of PSTC, we designed an assay to measure IL-1-induced nuclear exhibited by the positive control IKK2 inhibitor (Fig. 5A) . In contrast, the Nrf2 activators PSTC and DMF showed little or no inhibition of NF-B translocation at concentrations up to 10 M.
To test whether our compound would inhibit mTOR signaling, we used HEK293 cells stimulated with 100 nM insulin and measured the phosphorylation of S6 ribosomal protein, a key downstream target of mTOR. When cells were pre-treated with SFN (10 M) or CDDO-Me (1 M) the insulin-induced increase in the phospho/total S6 ratio was inhibited (Fig. 5B) . This effect was similar to rapamycin (20 nM), a known inhibitor of mTOR signaling. In contrast, PSTC (10 M) and DMF (30 M) had no effect on insulin-induced phospho/total S6 levels. These results suggest that PSTC lacks the NF-B and mTOR activity previously reported for CDDO-Me (Ahmad et al., 2006; Deeb et al., 2007) and SFN (Xu et al., 2005; Wiczk et al., 2012) and may instead be more specific than these compounds for the Nrf2 pathway.
PSTC Engages Nrf2-Dependent Gene Expression in COPD Patient-Derived
Epithelial Cells Maintained in ALI Culture. Published reports suggest that the Nrf2 antioxidant system may be compromised or dysfunctional in COPD patients (Goven et al., 2008; Yamada et al., 2016) . Therefore it is important to evaluate a drug's ability to engage the mechanism in a translational disease setting. For this purpose we tested the ability of PSTC to 
concentration-dependent increases in the gene expression of NQO1, HO-1, GCLM, and
TXNRD1 with pEC50s of 6.6, 6.0, 6.4, and 6.5, respectively (Fig. 6 ). These results demonstrate the ability of PSTC to engage the Nrf2 pathway in human disease-derived cells and provide a translational model for Nrf2 engagement in COPD. nM respectively, and blood levels of the corresponding hydroxy-acid were 395.6 + 53.7 nM and 2,309.9 + 494.1 nM, respectively. Lung tissue was collected after 6 hours for analysis of mRNA levels and after 48 hours for the analysis of enzyme activity. Compared to vehicle-treated mice, PSTC-treated mice exhibited a dose-dependent increase in Nqo1 gene expression (Fig. 7A) , consistent with the dose-dependent increase observed in NQO1 activity (Fig. 7B) . Similarly, expression of the Nrf2-regulated genes Ho-1, Srxn1 and Txnrd1 increased in a dose-dependent manner following administration of PSTC. These results demonstrate engagement of the Nrf2 pathway by PSTC in vivo.
In Vivo

PSTC Inhibits Cigarette Smoke-Induced Pulmonary Inflammation in Mice.
To assess the effects of PSTC in an in vivo model of cigarette smoke-induced pulmonary inflammation, mice were administered PSTC at 1, 3, 10 or 30 mol/kg, p.o. once daily for 4 consecutive days, concomitant with cigarette smoke exposure on the final 3 days of dosing.
One hour following the final compound administration on day 4, blood levels of PSTC were 17.4 + 2.3 nM, 37.9 + 4.0 nM, 63.9 + 7.3 nM and 142.2 + 13.4 nM respectively, and blood levels of the corresponding hydroxy-acid were 108.6 + 8.9 nM, 264. Txnrd1 gene expression compared to vehicle-treated/air-exposed mice (Fig. 8) . Vehicletreated/smoke-exposed mice exhibited trends toward increased gene expression, which did not achieve statistical significance, compared to vehicle-treated/air-exposed mice. Twenty hours following the final compound dose, vehicle-treated/smoke-exposed mice exhibited significantly increased BAL fluid total cell (Fig. 9A) , neutrophil (Fig. 9B) , and mononuclear cell (Fig. 9C) numbers, and significantly increased lung KC (CXCL1) levels (Fig. 9D ), compared to vehicletreated/air-exposed mice. PSTC inhibited the smoke-induced increase in each cell subset, as well as in KC levels, in a dose-dependent manner. These data indicate that PSTC attenuates cigarette smoke-induced pulmonary inflammation in vivo. (Fig. 10A ), followed by a dose-dependent increase of NQO1 activity at 48 hours post-dose (Fig. 10B) . The dose-dependent increases observed in Ho-1 (Fig.   10C ), Srxn1 (Fig. 10D) and Txnrd1 (Fig. 10E ) gene expression further support the conclusion that in vivo administration of PSTC results in engagement of the Nrf2 pathway in rats.
In Vivo
PSTC Inhibits Ozone-Induced Pulmonary Inflammation and Restores Lung
Glutathione Levels in Rats. In a second model of oxidative stress/pulmonary inflammation, treatment of rats with PSTC (10 mol/kg) 24 hours prior to ozone exposure resulted, at 15 minutes post-ozone exposure, in significant inhibition of the ozone-induced increases in BAL fluid total cell (Fig. 11A) , neutrophil (Fig 11B) , and mononuclear cell (Fig. 11C ) numbers, and JPET #241794
-23 -significant restoration of the ozone-induced depletion of lung glutathione levels (Fig. 11D ).
These results indicate that PSTC attenuates both the pulmonary inflammation and glutathione depletion induced by ozone in the rat.
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Discussion
Development of new therapies to address unmet needs, especially those that can slow disease progression in COPD, is of utmost importance to patients and clinicians (Patalano et al., 2014) . Oxidative stress plays an important role in COPD, and thus has garnered attention as a potential area for new therapies. Several aspects of COPD are associated with an impaired response to oxidative stress, including potential generation of damage-associated molecular pattern molecules from chronic cigarette smoke exposure (Guo et al., 2008) , suppression of histone deacetylase 2 activity which can amplify inflammatory responses (Osoata et al., 2009) and lead to corticosteroid resistance (Ito et al., 2006) , and disruption of innate immune defenses associated with acute exacerbations (Berenson et al., 2006) . More specifically, evidence has suggested that the master redox regulator Nrf2 is defective in COPD (Hillas et al., 2013) Nrf2 has previously been demonstrated in both human cell systems and rodent in vivo models (Thimmulappa et al., 2006; Kode et al., 2008) . Furthermore, the Nrf2 activators CDDO-Me, SFN and DMF have been shown to modify glutathione levels (Reisman et al, 2012, Tarozzi et This article has not been copyedited and formatted. The final version may differ from this version. -25 -al., 2009 -25 -al., , Brennan et al, 2015 . Maintenance of glutathione homeostasis is critical as glutathione is the major endogenous non-protein thiol in cells and plays a key role in redox status (Forman and Dickinson, 2003) . Moreover, glutathione is important in the lung, defending the airways from damage in response to oxidants and inflammation (Biswas and Rahman, 2009) .
A key factor in drug discovery is the ability to demonstrate that compound activity in normal cells and naïve animals translates into efficacy in disease models. As previously noted, Nrf2 signaling has been reported to be defective in COPD patients (Goven et al., 2008; Yamada et al., 2016) , and therefore it is important to determine if PSTC activates Nrf2 in disease cells. In an ALI culture model of epithelial cells from bronchial brushings of COPD patients, the compound was able to engage the Nrf2 pathway, inducing the expression of multiple Nrf2-regulated genes in a concentration-dependent manner. Similarly, in an acute cigarette smoke exposure model, PSTC increased Nrf2-regulated gene expression in the lungs of mice. This engagement of the target in challenged mice was followed by dose-dependent inhibition of leukocyte influx into the BAL fluid. Likewise, in an ozone model of pulmonary oxidative stress, PSTC decreased BAL fluid leukocyte numbers in rats. The anti-inflammatory effects exhibited by this Nrf2 activator are consistent with the elevated leukocyte numbers observed in the BAL fluid of cigarette smoke-exposed Nrf2 gene-deficient mice, compared to wild type control mice (Rangasamy et al, 2004) . Collectively, in both in vitro and in vivo disease systems PSTC demonstrated target engagement, anti-inflammatory effects and the reversal of glutathione depletion, suggesting its potential efficacy in the treatment of COPD.
A primary goal of the work described herein was to develop a potent and selective activator of Nrf2. In the NQO1 enzyme activity assay in BEAS-2B cells, the potency exhibited by PSTC was markedly increased compared to SFN and DMF, and within a log of the potency exhibited by CDDO-Me. With regard to selectivity, both CDDO-Me (Ahmad et al., 2006) and SFN (Xu et al., 2005) have been reported to inhibit NF-B signaling, and indeed attenuated NF- PSTC or DMF demonstrated activity, consistent with published reports (Deeb et al., 2007; Wiczk et al, 2012) . Furthermore, in a selectivity panel containing 50 enzymes, receptors, ion channels and phenotypic cell health screens, CDDO-Me exhibited activity against 19 targets, while PSTC and SFN were each active against a single target, and DMF was inactive. Collectively, these results indicate that PSTC exhibits relatively comparable potency but greater selectivity than CDDO-Me, increased potency and selectivity compared to SFN, and increased potency but marginally less selectivity than DMF.
In summary, we have demonstrated that PSTC is a potent and selective activator of the 
